The American journal of managed care
-
To examine the relationship between care experiences and inpatient opioid receipt during and after delivery for women hospitalized for vaginal delivery (VD). ⋯ Receipt of opioids may not be a significant determinant of the pain-specific patient care experiences of women hospitalized for VD.
-
To assess provider and patient preferences for an oncologist selection tool, value-based care, involvement in cancer care, and end-of-life planning. ⋯ These results present a compelling rationale for developing a data-driven oncologist selection tool, optimizing patient and provider involvement in care, and expanding the portion of patients who have an advance directive at the start of their cancer care to optimize their cancer journey.
-
Covishield and Covaxin vaccines have been introduced after rapid approval in India, the nation that has the second most COVID-19 cases globally. These vaccines have been administered in a 2-dose schedule since January 16, 2021. This study deals with the clinical profile of individuals who developed COVID-19 infection post COVID-19 vaccination. This is the first study of its kind in India. ⋯ The findings of this study should boost the ongoing initiative of maximizing the vaccinated population countrywide and emphasize the need for 2 doses of vaccination.
-
The annual special issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care® (AJMC), features coverage of the 2022 Annual Meeting of the American Society of Clinical Oncology, held June 3-7, 2022, in Chicago, Illinois. Clinical trials presented during the meeting and summarized in the issue include DESTINY-Breast04, DETERMINATION, SHINE, and ECHELON-1. ⋯ A final section features clinical findings presented by scientists affiliated with Strategic Alliance Partners of AJMC. Each issue section includes an interview with a key opinion leader participating in the meeting.
-
To examine the use of step therapy, prior authorization, and Part D formulary exclusion by 4 large Medicare Advantage (MA) insurers to manage 20 physician-administered drugs with the highest total Medicare expenditures (top 20 drugs). ⋯ Four large MA insurers managed access to expensive physician-administered drugs with a combination of prior authorization, step therapy, and Part D formulary design. When a low-cost alternative exists, these tools can help reduce wasteful spending, but the administrative barriers may also reduce access.